162 related articles for article (PubMed ID: 38555398)
1. SDCBP modulates tumor microenvironment, tumor progression and anti-PD1 efficacy in colorectal cancer.
Yu J; Yu S; Bai J; Zhu Z; Gao Y; Li Y
Cancer Gene Ther; 2024 May; 31(5):755-765. PubMed ID: 38555398
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.
Doleschel D; Hoff S; Koletnik S; Rix A; Zopf D; Kiessling F; Lederle W
J Exp Clin Cancer Res; 2021 Sep; 40(1):288. PubMed ID: 34517894
[TBL] [Abstract][Full Text] [Related]
3. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation.
Liu J; Bai W; Zhou T; Xie Y; Yang B; Sun J; Wang Y; Li X; Hou X; Liu Z; Fu D; Yan J; Jiang W; Zhao K; Zhou B; Yuan S; Guo Y; Wang H; Chang A; Gao S; Shi L; Huang C; Yang S; Hao J
Gut; 2023 Sep; 72(9):1722-1737. PubMed ID: 36828627
[TBL] [Abstract][Full Text] [Related]
4. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer.
Yang M; Huang Q; Li C; Jiang Z; Sun J; Wang Z; Liang R; Li D; Li B; Zhao H
Front Immunol; 2021; 12():647540. PubMed ID: 33897695
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
6. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
7. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization.
Lin X; Wang S; Sun M; Zhang C; Wei C; Yang C; Dou R; Liu Q; Xiong B
J Hematol Oncol; 2019 Feb; 12(1):20. PubMed ID: 30808369
[TBL] [Abstract][Full Text] [Related]
8. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC.
Huang C; Ou R; Chen X; Zhang Y; Li J; Liang Y; Zhu X; Liu L; Li M; Lin D; Qiu J; Liu G; Zhang L; Wu Y; Tang H; Liu Y; Liang L; Ding Y; Liao W
J Exp Clin Cancer Res; 2021 Sep; 40(1):304. PubMed ID: 34583750
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
11. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer.
Zhang XL; Hu LP; Yang Q; Qin WT; Wang X; Xu CJ; Tian GA; Yang XM; Yao LL; Zhu L; Nie HZ; Li Q; Xu Q; Zhang ZG; Zhang YL; Li J; Wang YH; Jiang SH
Oncogene; 2021 Jun; 40(23):3959-3973. PubMed ID: 33986509
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
14. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
[TBL] [Abstract][Full Text] [Related]
15. Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages.
Wang D; Wang X; Si M; Yang J; Sun S; Wu H; Cui S; Qu X; Yu X
Cancer Lett; 2020 Apr; 474():36-52. PubMed ID: 31931030
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of zinc carnosine in the treatment of colorectal cancer and its potential in combination with immunotherapy
Tang W; Liu H; Li X; Ooi TC; Rajab NF; Cao H; Sharif R
Aging (Albany NY); 2022 Nov; 14(21):8688-8699. PubMed ID: 36375474
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
18. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
19. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
20. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
